Floatz logo

Ziconotide

Peripheral Neuropathy

Aaron Bosterprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Peripheral Neuropathy cohort.

Asset / SponsorPhaseRating
Pregabalin
University of Rochester
Phase 4A
Lidocaine
University of Utah
Phase 4BBB
Nabiximols
VA Office of Research and Development
Phase 3BBB
Xaliplatin
Tanta University
Phase 3BBB
Gabapentin
Washington University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Ziconotide is also rated in:

neuralgiaDormant
BB
Indicative · Phase 4
66 / 100
View asset →
spinal cord disorderDormant
BB
Indicative · Phase 4
65 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →